ReviewClinical & translational immunology2020
The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies.
Review in Clinical & translational immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Tumour progression shows decrease in PD-L1 expression in matched metastases/primary uveal melanomas.Acta ophthalmologica · 2026Article
- Pan-cancer screening, bioinformatics analysis, and experimental validation identify TEX10 as a key biomarker driving OSCC progression.Frontiers in genetics · 2026Article
- Review
- Recent developments in immunotherapy for gastrointestinal tract cancers.Journal of hematology & oncology · 2024Review
- Spatial mapping of the DNA adducts in cancer.DNA repair · 2023Review
- A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer.Genome medicine · 2023Article
- Potential predictors of immunotherapy in small cell lung cancer.Pathology oncology research : POR · 2023Review
- Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.Frontiers in immunology · 2023Article
- Immune Checkpoint Inhibitors in Cancer Therapy.Current oncology (Toronto, Ont.) · 2022Review
- Advances in mass cytometry and its applicability to digital pathology in clinical-translational cancer research.Advances in laboratory medicine · 2022Review
- Opportunities and Challenges in Understanding Atherosclerosis by Human Biospecimen Studies.Frontiers in cardiovascular medicine · 2022Review
- Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.Frontiers in immunology · 2022Article
- Understanding the tumor microenvironment in head and neck squamous cell carcinoma.Clinical & translational immunology · 2022Review
- Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas.Frontiers in immunology · 2022Article
- Emerging role of circulating tumor cells in immunotherapy.Theranostics · 2021Review
- The Effects of COVID-19 on the Placenta During Pregnancy.Frontiers in immunology · 2021Review
- Spatial Profiles of Intratumoral PD-1Frontiers in immunology · 2021Article
- Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients.Frontiers in oncology · 2020Article
- Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapies have shown long-lasting and unparalleled responses for cancer patients compared to conventional therapy. However, they seem to only be effective in a subset of patients. Therefore, it has become evident that a greater understanding of the tumor microenvironment (TME) is required to understand the nuances which may be at play for a favorable outcome to therapy. The immune contexture of the TME is an important factor in dictating how well a tumor may respond to immune checkpoint inhibitors. While traditional immunohistochemistry techniques allow for the profiling of cells in the tumor, this is often lost when tumors are analysed using bulk tissue genomic approaches. Moreover, the actual cellular proportions, cellular heterogeneity and deeper spatial distribution are lacking in characterisation. Advances in tissue interrogation technologies have given rise to spatially resolved characterisation of the TME. This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated with a favorable outcome to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.